Depomed Inc (DEPO) 18.38 $DEPO
Depomed To Report Fourth Quarter Fiscal Year 2014 Financial Results On Monday, February 23, 2015
PR Newswire - Thu Feb 12, 7:00AM CST
Depomed, Inc. (NASDAQ
EPO) today announced that it will release fourth quarter fiscal year 2014 financial results after the market closes on Monday, February 23, 2015. The Company will host a conference call beginning at 4:30 pm EST, 1:30 pm PST to discuss its results.
DEPO: 18.38 (+0.20)
Depomed Up 47.3% Since SmarTrend Uptrend Call (DEPO)
Comtex SmarTrend(R) - Wed Feb 11, 9:34AM CST
SmarTrend identified an Uptrend for Depomed (NASDAQ EPO) on August 11th, 2014 at $12.34. In approximately 6 months, Depomed has returned 47.33% as of today's recent price of $18.18.
DEPO: 18.38 (+0.20)
New American Headache Society Assessment of Acute Migraine Treatments Highlights Effective Therapies Based on Strength of Evidence
PR Newswire - Mon Feb 09, 7:00AM CST
A new evidence-based assessment of acute migraine treatments published in the current issue of the American Headache Society (AHS) journal Headache has established diclofenac potassium as an effective (Level A) treatment for acute migraine attacks. The first assessment of acute migraine treatments developed in the last 14 years reinforces CAMBIA® (Diclofenac Potassium for Oral Solution), a prescription medicine marketed by Depomed, Inc. (NASDAQ: DEPO), as a stand-alone option for treating migraines in adults, based on similar evidence for efficacy as seen with migraine-specific medicines. Furthermore, it augments diclofenac potassium's position from the American Academy of Neurology (AAN) 2000 Guidelines for acute treatment of migraine, in which diclofenac potassium was described as "probably effective."
DEPO: 18.38 (+0.20)
Depomed Has Returned 41.8% Since SmarTrend Recommendation (DEPO)
Comtex SmarTrend(R) - Wed Feb 04, 9:06AM CST
SmarTrend identified an Uptrend for Depomed (NASDAQ EPO) on August 11th, 2014 at $12.34. In approximately 6 months, Depomed has returned 41.82% as of today's recent price of $17.50.
DEPO: 18.38 (+0.20)
Depomed To Present At Healthcare Conferences In February
PR Newswire - Wed Feb 04, 7:00AM CST
Depomed, Inc. (NASDAQ EPO) today announced that it will be presenting at two healthcare conferences in February.
DEPO: 18.38 (+0.20)
Depomed Acquires Nucynta Franchise From J&J
Jason Napodano, CFA - at Seeking Alpha - Tue Jan 20, 11:30AM CST
JNJ: 99.62 (+1.18), DEPO: 18.38 (+0.20)
Depomed Shares Up 58.3% Since SmarTrend's Buy Recommendation (DEPO)
Comtex SmarTrend(R) - Tue Jan 20, 10:51AM CST
SmarTrend identified an Uptrend for Depomed (NASDAQ EPO) on August 11th, 2014 at $12.34. In approximately 5 months, Depomed has returned 58.35% as of today's recent price of $19.54.
DEPO: 18.38 (+0.20)
Now Trending on Wall Street: New Research on E2open, Baker Hughes, Goldman Sachs, Altisource Portfolio and Depomed
PR Newswire - Mon Jan 19, 6:40AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including E2open (NASDAQ: EOPN), Baker Hughes (NYSE: BHI), Goldman Sachs (NYSE: GS), Altisource Portfolio (NASDAQ: ASPS), and Depomed (NASDAQ: DEPO). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
GS: 189.00 (-0.78), ASPS: 22.32 (+0.09), EOPN: 8.55 (-0.01), DEPO: 18.38 (+0.20), BHI: 64.31 (+1.93)
Depomed
at Investor's Business Daily - Fri Jan 16, 5:35PM CST
Depomed (DEPO) got an upgrade from Roth after it inked a deal to acquire the Nucynta pain drug franchise from the Johnson & Johnson (JNJ) Janssen Pharmaceuticals division for $1.05 bil. Shares spiked 14.5% to 20.20.
JNJ: 99.62 (+1.18), DEPO: 18.38 (+0.20)
Nasdaq stocks posting largest percentage increases
AP - Fri Jan 16, 5:20PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
FLML: 14.15 (+0.15), EOPN: 8.55 (-0.01), DEPO: 18.38 (+0.20), NYNY: 6.33 (+0.06), CRRC: 22.96 (+0.22), AREX: 8.15 (+0.27)
SmarTrend Watching for Potential Pullback in Shares of Depomed After 14.45% Gain
Comtex SmarTrend(R) - Fri Jan 16, 4:39PM CST
Depomed (NASDAQ EPO) traded in a range yesterday that spanned from a low of $17.76 to a high of $20.24. Yesterday, the shares gained 14.4%, which took the trading range above the 3-day high of $18.28 on volume of 6.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
DEPO: 18.38 (+0.20)
Precision Castparts and UBS are big market movers
AP - Fri Jan 16, 3:41PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:
AMKR: 8.90 (-0.02), JNJ: 99.62 (+1.18), VIA: 69.08 (+1.02), TSRA: 39.27 (-0.05), DEPO: 18.38 (+0.20), UBS: 17.19 (+0.21), CRRC: 22.96 (+0.22), PCP: 205.54 (+1.37), VIAB: 68.98 (+1.27), RGC: 23.23 (+1.35)
Depomed Hits High On Big Pain-Drug Deal With J&J
at Investor's Business Daily - Fri Jan 16, 10:32AM CST
Specialty drugmaker Depomed (DEPO) popped nearly 10% to a new high and got an upgrade from Roth Friday after it inked a deal to acquire a new pain drug for $1.05 billion. Late Thursday, Depomed agreed to buy the Nucynta franchise from the Johnson &...
JNJ: 99.62 (+1.18), DEPO: 18.38 (+0.20)
Depomed (DEPO) Stock Gains Today on NUCYNTA Acquisition
at The Street - Fri Jan 16, 10:02AM CST
Depomed (DEPO) shares are climbing after the company purchased NUCYNTA from Janssen Pharmaceuticals for $1.05 billion.
DEPO: 18.38 (+0.20)
Upgrade Alert for Depomed (DEPO)
Comtex SmarTrend(R) - Fri Jan 16, 8:02AM CST
Depomed (NASDAQ EPO) was upgraded from Neutral to Buy at Roth Capital today. The stock closed yesterday at $17.65 on volume of 649,000 shares, below average daily volume of 756,000. Potential upside of 8.4% exists for Depomed, based on a current level of $17.65 and analysts' average consensus price target of $19.12. The stock should find initial support at its 50-day moving average (MA) of $15.73 and further support at its 200-day MA of $13.98.
DEPO: 18.38 (+0.20)
Pre-Market Pulse on Pharma Stocks - Teva Pharma Industries, Allergan, Endo Intl., Akorn, and Depomed
PR Newswire - Fri Jan 16, 7:30AM CST
Investor-Edge has initiated coverage on the following equities: Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Allergan Inc. (NYSE: AGN), Endo International PLC (NASDAQ: ENDP), Akorn Inc. (NASDAQ: AKRX), and Depomed Inc. (NASDAQ: DEPO). Free research reports can be accessed at: http://investor-edge.com/register. On Thursday, January 15, 2015, the NASDAQ Composite ended at 4,570.82, down 1.48%, the Dow Jones Industrial Average declined 0.61%, to finish the day at 17,320.71, and the S&P 500 closed at 1,992.67, down 0.92%. The losses were broad based as eight out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 799.29, down 1.07%, while the index has advanced 14.16% in the previous three months. Register for your complimentary reports at:
AGN: 229.49 (+1.87), ENDP: 84.01 (+1.12), AKRX: 47.28 (-0.25), DEPO: 18.38 (+0.20), TEVA: 56.77 (-0.58)
DEPOMED
at Investor's Business Daily - Thu Jan 15, 5:37PM CST
DEPOMED (DEPO), a drug company, acquired U.S. rights to pain drug Nucynta from Janssen Pharma for $1.05 bil. Shares rose 4.3%.
DEPO: 18.38 (+0.20)
DepoMed to buy U.S. rights to Nucynta from J&J unit for $1.05B
Seeking Alpha - at Seeking Alpha - Thu Jan 15, 4:52PM CST
JNJ: 99.62 (+1.18), DEPO: 18.38 (+0.20)
Depomed To Report Fourth Quarter Fiscal Year 2014 Financial Results On Monday, February 23, 2015
PR Newswire - Thu Feb 12, 7:00AM CST
Depomed, Inc. (NASDAQ
EPO) today announced that it will release fourth quarter fiscal year 2014 financial results after the market closes on Monday, February 23, 2015. The Company will host a conference call beginning at 4:30 pm EST, 1:30 pm PST to discuss its results. DEPO: 18.38 (+0.20)
Depomed Up 47.3% Since SmarTrend Uptrend Call (DEPO)
Comtex SmarTrend(R) - Wed Feb 11, 9:34AM CST
SmarTrend identified an Uptrend for Depomed (NASDAQ
EPO) on August 11th, 2014 at $12.34. In approximately 6 months, Depomed has returned 47.33% as of today's recent price of $18.18. DEPO: 18.38 (+0.20)
New American Headache Society Assessment of Acute Migraine Treatments Highlights Effective Therapies Based on Strength of Evidence
PR Newswire - Mon Feb 09, 7:00AM CST
A new evidence-based assessment of acute migraine treatments published in the current issue of the American Headache Society (AHS) journal Headache has established diclofenac potassium as an effective (Level A) treatment for acute migraine attacks. The first assessment of acute migraine treatments developed in the last 14 years reinforces CAMBIA® (Diclofenac Potassium for Oral Solution), a prescription medicine marketed by Depomed, Inc. (NASDAQ: DEPO), as a stand-alone option for treating migraines in adults, based on similar evidence for efficacy as seen with migraine-specific medicines. Furthermore, it augments diclofenac potassium's position from the American Academy of Neurology (AAN) 2000 Guidelines for acute treatment of migraine, in which diclofenac potassium was described as "probably effective."
DEPO: 18.38 (+0.20)
Depomed Has Returned 41.8% Since SmarTrend Recommendation (DEPO)
Comtex SmarTrend(R) - Wed Feb 04, 9:06AM CST
SmarTrend identified an Uptrend for Depomed (NASDAQ
EPO) on August 11th, 2014 at $12.34. In approximately 6 months, Depomed has returned 41.82% as of today's recent price of $17.50. DEPO: 18.38 (+0.20)
Depomed To Present At Healthcare Conferences In February
PR Newswire - Wed Feb 04, 7:00AM CST
Depomed, Inc. (NASDAQ
EPO) today announced that it will be presenting at two healthcare conferences in February. DEPO: 18.38 (+0.20)
Depomed Acquires Nucynta Franchise From J&J
Jason Napodano, CFA - at Seeking Alpha - Tue Jan 20, 11:30AM CST
JNJ: 99.62 (+1.18), DEPO: 18.38 (+0.20)
Depomed Shares Up 58.3% Since SmarTrend's Buy Recommendation (DEPO)
Comtex SmarTrend(R) - Tue Jan 20, 10:51AM CST
SmarTrend identified an Uptrend for Depomed (NASDAQ
EPO) on August 11th, 2014 at $12.34. In approximately 5 months, Depomed has returned 58.35% as of today's recent price of $19.54. DEPO: 18.38 (+0.20)
Now Trending on Wall Street: New Research on E2open, Baker Hughes, Goldman Sachs, Altisource Portfolio and Depomed
PR Newswire - Mon Jan 19, 6:40AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including E2open (NASDAQ: EOPN), Baker Hughes (NYSE: BHI), Goldman Sachs (NYSE: GS), Altisource Portfolio (NASDAQ: ASPS), and Depomed (NASDAQ: DEPO). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
GS: 189.00 (-0.78), ASPS: 22.32 (+0.09), EOPN: 8.55 (-0.01), DEPO: 18.38 (+0.20), BHI: 64.31 (+1.93)
Depomed
at Investor's Business Daily - Fri Jan 16, 5:35PM CST
Depomed (DEPO) got an upgrade from Roth after it inked a deal to acquire the Nucynta pain drug franchise from the Johnson & Johnson (JNJ) Janssen Pharmaceuticals division for $1.05 bil. Shares spiked 14.5% to 20.20.
JNJ: 99.62 (+1.18), DEPO: 18.38 (+0.20)
Nasdaq stocks posting largest percentage increases
AP - Fri Jan 16, 5:20PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
FLML: 14.15 (+0.15), EOPN: 8.55 (-0.01), DEPO: 18.38 (+0.20), NYNY: 6.33 (+0.06), CRRC: 22.96 (+0.22), AREX: 8.15 (+0.27)
SmarTrend Watching for Potential Pullback in Shares of Depomed After 14.45% Gain
Comtex SmarTrend(R) - Fri Jan 16, 4:39PM CST
Depomed (NASDAQ
EPO) traded in a range yesterday that spanned from a low of $17.76 to a high of $20.24. Yesterday, the shares gained 14.4%, which took the trading range above the 3-day high of $18.28 on volume of 6.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. DEPO: 18.38 (+0.20)
Precision Castparts and UBS are big market movers
AP - Fri Jan 16, 3:41PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:
AMKR: 8.90 (-0.02), JNJ: 99.62 (+1.18), VIA: 69.08 (+1.02), TSRA: 39.27 (-0.05), DEPO: 18.38 (+0.20), UBS: 17.19 (+0.21), CRRC: 22.96 (+0.22), PCP: 205.54 (+1.37), VIAB: 68.98 (+1.27), RGC: 23.23 (+1.35)
Depomed Hits High On Big Pain-Drug Deal With J&J
at Investor's Business Daily - Fri Jan 16, 10:32AM CST
Specialty drugmaker Depomed (DEPO) popped nearly 10% to a new high and got an upgrade from Roth Friday after it inked a deal to acquire a new pain drug for $1.05 billion. Late Thursday, Depomed agreed to buy the Nucynta franchise from the Johnson &...
JNJ: 99.62 (+1.18), DEPO: 18.38 (+0.20)
Depomed (DEPO) Stock Gains Today on NUCYNTA Acquisition
at The Street - Fri Jan 16, 10:02AM CST
Depomed (DEPO) shares are climbing after the company purchased NUCYNTA from Janssen Pharmaceuticals for $1.05 billion.
DEPO: 18.38 (+0.20)
Upgrade Alert for Depomed (DEPO)
Comtex SmarTrend(R) - Fri Jan 16, 8:02AM CST
Depomed (NASDAQ
EPO) was upgraded from Neutral to Buy at Roth Capital today. The stock closed yesterday at $17.65 on volume of 649,000 shares, below average daily volume of 756,000. Potential upside of 8.4% exists for Depomed, based on a current level of $17.65 and analysts' average consensus price target of $19.12. The stock should find initial support at its 50-day moving average (MA) of $15.73 and further support at its 200-day MA of $13.98. DEPO: 18.38 (+0.20)
Pre-Market Pulse on Pharma Stocks - Teva Pharma Industries, Allergan, Endo Intl., Akorn, and Depomed
PR Newswire - Fri Jan 16, 7:30AM CST
Investor-Edge has initiated coverage on the following equities: Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Allergan Inc. (NYSE: AGN), Endo International PLC (NASDAQ: ENDP), Akorn Inc. (NASDAQ: AKRX), and Depomed Inc. (NASDAQ: DEPO). Free research reports can be accessed at: http://investor-edge.com/register. On Thursday, January 15, 2015, the NASDAQ Composite ended at 4,570.82, down 1.48%, the Dow Jones Industrial Average declined 0.61%, to finish the day at 17,320.71, and the S&P 500 closed at 1,992.67, down 0.92%. The losses were broad based as eight out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 799.29, down 1.07%, while the index has advanced 14.16% in the previous three months. Register for your complimentary reports at:
AGN: 229.49 (+1.87), ENDP: 84.01 (+1.12), AKRX: 47.28 (-0.25), DEPO: 18.38 (+0.20), TEVA: 56.77 (-0.58)
DEPOMED
at Investor's Business Daily - Thu Jan 15, 5:37PM CST
DEPOMED (DEPO), a drug company, acquired U.S. rights to pain drug Nucynta from Janssen Pharma for $1.05 bil. Shares rose 4.3%.
DEPO: 18.38 (+0.20)
DepoMed to buy U.S. rights to Nucynta from J&J unit for $1.05B
Seeking Alpha - at Seeking Alpha - Thu Jan 15, 4:52PM CST
JNJ: 99.62 (+1.18), DEPO: 18.38 (+0.20)
